NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Excellent research. But read between the lines and it's very unlikely MHRA will approve L based on the Plll. Not even a peep about NWBO in that PR. Had LP managed her shareholder's company right this research whould've been NWBO's not UCLA's.


So much time lost.

>>While this association was statistically significant and suggests a potential link between this treatment and improved survival rates, the study was not originally designed to measure survival rates of this treatment. As such, the authors emphasized the need for caution regarding true clinical benefits of this combination treatment.

I could see MHRA / NICE perhaps working with L to provide some subset after another trial.

>>This means we could test patients for this specific immune response, and if it’s strong, we know they are likely to respond well to the combined TLR agonist and dendritic cell vaccine therapy.”